New probiotic research targeting children and infants
By Stephen Daniells
- Last updated on
Sticking with infants and children, Dr Niklas Larsson, Research Director, Probi, discussed the results of specific clinical trials, including:
1. The safety and colonization frequency in infants from 4-days of age, supplemented with Lactobacillus rhamnosus 6594 and L. plantarum HEAL9 for 8 weeks. 2. The effects of L. plantarum 299v in children receiving antibiotics, to prevent and/or reduce symptoms of antibiotic-associated diarrhea and loose and watery stools. 3. The effects of L. plantarum HEAL9 and L. paracasei 8700:2 in children to prevent or reduce the severity and duration of common colds.
Dr Larsson also presented intriguing data from a clinical trial investigating if a combination of two Lactobacilli strains could affect immunological activity in children with celiac disease autoimmunity.